Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Disabling ItpkB enzyme improves function of Natural Killer cells

Researchers at The Scripps Research Institute (TRSI) are fueling the future of cancer treatment by improving a powerful tool in disease defense: the body's immune system. By revealing a novel but widespread cell signaling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

29 Nov 2012

Trovagene develops first molecular diagnostic test to detect KRAS mutations from urine samples

Trovagene, Inc. today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.

28 Nov 2012

Researchers aim to improve feeling of 'walking on marbles' for arthritis patients

Researchers at the University of Southampton are to undertake a new stage of a study aimed at improving the health and mobility of those suffering from the common complaint of 'walking on marbles' associated with Rheumatoid Arthritis (RA) in the feet.

28 Nov 2012

Researchers discover molecular basis for potential cancer preventive effects of vitamin D

A team of researchers at McGill University have discovered a molecular basis for the potential cancer preventive effects of vitamin D. The team, led by McGill professors John White and David Goltzman, of the Faculty of Medicine's Department of Physiology, discovered that the active form of vitamin D acts by several mechanisms to inhibit both the production and function of the protein cMYC.

26 Nov 2012

Elsevier announces launch of Leukemia Research Reports journal

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open access, online journal, Leukemia Research Reports.

26 Nov 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Synta Pharmaceuticals Corp. announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan.

26 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Study to discover exactly how intravenous immune globulin treatments work

Immune globulin replacement began decades ago as a treatment for patients who could not make their own protective antibodies, but has proven to have much broader benefits than originally expected.

22 Nov 2012

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.

21 Nov 2012

Rituximab may help patients with aPL-related clinical problems

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.

21 Nov 2012

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation for Cancer Research today announced grant recipients of its first-ever Collaborative Research grant program. The inaugural awards total $800,000 for two groundbreaking research initiatives that span the medical capitals of New York, Boston and Chicago.

21 Nov 2012

No advantage of continuous over bolus doxorubicin in ALL children

Research suggests that there is no long-term advantage, in terms of cardioprotection or event-free survival, from giving continuous instead of bolus doxorubicin infusion in children with acute lymphoblastic leukemia.

20 Nov 2012

Tanshinones protect against sepsis: Study

Researchers at The Feinstein Institute for Medical Research have discovered that tanshinones, which come from the plant Danshen and are highly valued in Chinese traditional medicine, protect against the life-threatening condition sepsis. The findings are published in the December issue of Biochemical Pharmacology.

16 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

Study reveals increased risk of leukemia among Chernobyl cleanup workers

A 20-year study following 110,645 workers who helped clean up after the 1986 Chernobyl nuclear power plant accident in the former Soviet territory of Ukraine shows that the workers share a significant increased risk of developing leukemia. The results may help scientists better define cancer risk associated with low doses of radiation from medical diagnostic radiation procedures such as computed tomography scans and other sources.

8 Nov 2012

Destruction of newborn screening left over samples may be detrimental to medical research

The tremendous potential public health benefits of research with blood samples left over after routine newborn screening must not be lost amidst controversy and litigation, say medical and bioethics experts in a commentary published in the journal Science Translational Medicine.

8 Nov 2012

Leukemia News and Research

Further Reading

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Disabling ItpkB enzyme improves function of Natural Killer cells

Trovagene develops first molecular diagnostic test to detect KRAS mutations from urine samples

Researchers aim to improve feeling of 'walking on marbles' for arthritis patients

Researchers discover molecular basis for potential cancer preventive effects of vitamin D

Elsevier announces launch of Leukemia Research Reports journal

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Study to discover exactly how intravenous immune globulin treatments work

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

Rituximab may help patients with aPL-related clinical problems

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

No advantage of continuous over bolus doxorubicin in ALL children

Tanshinones protect against sepsis: Study

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Study reveals increased risk of leukemia among Chernobyl cleanup workers

Destruction of newborn screening left over samples may be detrimental to medical research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News